Pre-Clinical Development, PTC Therapeutics, Warren, NJ, USA.
US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA.
Int J Toxicol. 2024 Sep-Oct;43(5):435-455. doi: 10.1177/10915818241259794. Epub 2024 Jul 20.
Nonclinical safety studies are typically conducted to establish a toxicity profile of a new pharmaceutical in clinical development. Such a profile may encompass multiple differing types of animal studies, or not! Some types of animal studies may not be warranted for a specific program or may only require a limited evaluation if scientifically justified. The goal of this course was to provide a practical perspective on regulatory writing of a dossier(s) using the weight of evidence (WOE) approach for carcinogenicity, drug abuse liability and pediatric safety assessments. These assessments are typically done after some clinical data are available and are highly bespoke to the pharmaceutical being developed. This manuscript will discuss key data elements to consider and strategy options with some case studies and examples. Additionally, US FDA experience with dossier(s) including WOE arguments is discussed.
非临床安全性研究通常用于在临床开发中建立新药物的毒性概况。这样的概况可能包括多种不同类型的动物研究,也可能没有!某些类型的动物研究可能不适用于特定的项目,或者如果从科学角度来看是合理的,则只需要进行有限的评估。本课程的目的是提供使用致癌性、药物滥用倾向和儿科安全性评估的证据权重 (WOE) 方法来编写档案文件的监管写作的实用视角。这些评估通常是在获得一些临床数据后进行的,并且高度针对正在开发的药物。本文将讨论一些案例研究和示例中需要考虑的关键数据元素和策略选项。此外,还讨论了美国 FDA 对包括 WOE 论证在内的档案文件的经验。